Next Article in Journal
Efficacy of Manual Therapy in Temporomandibular Joint Disorders and Its Medium-and Long-Term Effects on Pain and Maximum Mouth Opening: A Systematic Review and Meta-Analysis
Next Article in Special Issue
Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
Previous Article in Journal
Deciphering the Genetics of Primary Angioedema with Normal Levels of C1 Inhibitor
Previous Article in Special Issue
Chemokine Receptors CCR1 and CCR2 on Peripheral Blood Mononuclear Cells of Newly Diagnosed Patients with the CD38-Positive Chronic Lymphocytic Leukemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 11
10.3390/jcm9113403
Review Report
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

J. Clin. Med. 2020, 9(11), 3403; https://doi.org/10.3390/jcm9113403
by Pierluigi Masciopinto 1, Grazia Dell’Olio 1, Rosa De Robertis 1, Giorgina Specchia 2, Pellegrino Musto 1 and Francesco Albano 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2020, 9(11), 3403; https://doi.org/10.3390/jcm9113403
Submission received: 14 September 2020 / Revised: 2 October 2020 / Accepted: 22 October 2020 / Published: 23 October 2020
(This article belongs to the Special Issue Lymphoma：New Diagnosis and Current Treatment Strategies)

Round 1

Reviewer 1 Report

GENERAL COMMENTS

The authors present a review on “The role of autoimmune diseases in the prognosis of lymphoma” but the content of the paper is not focused on the prognostic role of autoimmune disorders in lymphomas. The authors could improve on their writing and structure forming. Documentation of the presented information in terms of references is also poor with many important studies having been omitted. Some specific comments are given below but the concerns regarding this paper is not limited to them.

SPECIFIC COMMENTS

  1. The manuscript is composed by separate unrelated paragraphs but does not follow a clear structure and a rational order of reporting.
  2. The introduction is too long. Its content should be split in separate paragraphs under separate headings or subheadings. Pathophysiology should be discussed separately.
  3. Paragraphs 2 and 3 have extremely limited documentation.
  4. Many associations of significant lymphoma subtypes are not adequately described (autoimmune cytopenias and CLL, autoimmune cytopenias and Hodgkin lymphoma, pure red cell aplasia and CLL, marginal zone and mantle cell lymphoma etc).
  5. Some data appear rather peculiar. For example the 50% frequency of anti-phospholipid antibodies in the serum of aggressive non-Hodgkin lymphomas sounds rather contradictory to common clinical experience and reference #18, which is cited to support this, appears unrelated.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

This is the review of autoimmune diseases (AID) in the lymphoma. AID can occur before, during, or after the treatment of NHL as described in 2 (Timing if AID in the lymphoma course). The mechanism of AID which occurs before NHL is different from the mechanism of AID which occurs during or after the treatment of NHL. Thus it is important to describe the mechanism of AID in each timing.

 

In Discussion, authors need to describe about the mechanism of AID in lymphoma. For example, AID which occurs before or during NHL may be associated with the lymphoma cells. However, AID which occurs after chemotherapy might be associated with imbalances of helper/suppressor T cell populations (Oka S, Acta haematologica 2019;141:79-83). The imbalances in T cell functions may lead to the over-reactivity of B cells and autoimmune phenomena.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop